Rockefeller Capital Management L.P. Sab Biotherapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$0.13 - $12.4 $39 - $3,720	300 Added 25.0%	1,500 $1,000
Q2 2022 Aug 12, 2022	BUY	$1.11 - $3.46 $111 - $346	100 Added 9.09%	1,200 $1,000
Q1 2022 May 13, 2022	BUY	$1.78 - $8.5 $712 - $3,400	400 Added 57.14%	1,100 $4,000
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $5,110 - $7,868	700 New	700 $5,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $111M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.